Clinical Management of Obesity (Technical Insights)


Regular Price: USD 4,950.00

Special Price USD 3,465.00

30% OFF

* Required Fields

Regular Price: USD 4,950.00

Special Price USD 3,465.00


Be the first to review this product

This research service provides an emerging technology analysis in the clinical management of obesity across the globe.

Table of Contents

Clinical Management of Obesity (Technical Insights) , Executive SummaryScope and MethodologyScope and SegmentationMethodologyKey FindingsAn Overview of the Weightloss IndustryNoteworthy Technology Developments--CompaniesNoteworthy Technology Developments--UniversitiesClinical Management of Obesity (Technical Insights) , Clinical Management of Obesity--Technology AnalysisObesity--OverviewDefinitionsCauses and Associated Health ProblemsTechnology PrimerDiet Therapy and Lifestyle ChangesPharmacotherapyBariatric SurgeryMedical DevicesTechnology Impact Analysis and Future TrendsClinical Management of Obesity (Technical Insights) , Technology Adoption Factor AnalysisPharmacotherapyTechnology AcceleratorsTechnology RoadblocksMedical DevicesTechnology AcceleratorsTechnology RoadblocksBariatric SurgeriesTechnology AcceleratorsTechnology RoadblocksFunding Analysis; Collaborations and MergersCompaniesUniversities and Government InstitutionsCollaborations and MergersClinical Management of Obesity (Technical Insights) , Advancements in Clinical Management of ObesityTechnology Innovations in Companies--North AmericaA Novel Antiobesity Drug Suppresses Appetite through Inhibition of Serotonin Reuptake--USAA Novel Appetite Suppressant Selectively Inhibits Cannabinoid Receptors--USAA Novel Small Molecule for the Treatment of Obesity--USAA Natural Peptide Hormone Suppresses Appetite and Enhances Metabolic Rate--USAGhrelin Receptor Modulators Offer Potential Obesity Treatment Options--CanadaNeurostimulation Technique to Treat Chronic Obesity--USAA Novel Small Molecule Drug to Treat Obesity--USAA Unique and Selective Hydroxy Tryptamine Receptor Agonist to Treat Obesity--USAA Novel and Selective Hydroxy Tryptamine Receptor Agonist for Obesity Treatment--USAA Novel Technology Leads to Apoptosis of Fat Cells--USAAdjustable and Reversible Gastric Banding Technique to Treat Morbid Obesity--USATechnology Innovations in Companies--EuropeAntiobesity Drug Works by Blocking Fat Absorption--UKPotent and Selective Cannabinoid Receptor Antagonists as Novel Antiobesity Agents--UKA Novel Single Peptide Drug with a Dual Receptor Agonist Action to Treat Obesity--DenmarkA Novel Antiobesity Drug Targets Thyroid Hormone Receptors--SwedenA Natural Appetite Suppressant from Korean Pine Nuts--NetherlandsA Unique Gastro Intestinal Lipase Inhibitor Aids Weight Loss--UKA Novel Vaccine Treats Obesity by Induction of Ghrelin Specific Antibodies--SwitzerlandTechnology Innovations in Companies--APACA Novel Peptide-Based Drug to Treat Obesity--AustraliaPotential Obesity Therapies through the Prevention of Adipogenesis--AustraliaA Pan Peroxisome Proliferator-Activated Receptor Agonist Burns Fat--IndiaCannabinoid Receptor Antagonist Drug Therapy for Obesity and Related Disorders--IndiaA Potential Antiobesity Drug Inhibits Alpha-Amylase--IndiaTechnology Innovations in Universities--WorldHormone Discovery Offers Hope for Obesity Drug--USAStomach Hormone Controls Appetite--UKStudy Finds Effect of Dietary Calcium on Weightloss--DenmarkResearch Finds Relationship between Metabolism and Appetite Suppression--AustraliaStudy Shows the Effect of Second Messenger Molecule on Satiety--UKClinical Management of Obesity (Technical Insights) , Patents and Key ContactsPatentsUS Patents--2006US Patents--2004 to 2005Key ContactsCompany ContactsUniversity ContactsClinical Management of Obesity (Technical Insights) , Frost and Sullivan 2006 Science and Technology AwardsExcellence in Technology AwardAward DescriptionAward RecipientProduct Innovation AwardAward DescriptionAward RecipientExcellence in Research AwardAward DescriptionAward RecipientClinical Management of Obesity (Technical Insights) , Decision Support DatabaseHealthcare and Pharmaceutical Expenditure--WorldTotal Healthcare Expenditure--World (1996 to 2006)Government Healthcare Expenditure--World (1996 to 2006)Private Healthcare Expenditure--World (1996 to 2006)Pharmaceutical R&D Expenditure--World (1996 to 2006)Healthcare Infrastructure--WorldNo. of Hospitals--World (1996 to 2006)No. of Physicians--World (1996 to 2006)No. of Pharmacists--World (1996 to 2006)Pervalence of Obesity-Related Health Risks--WorldPrevalence of Diabetes--World (1996 to 2006)Prevalence of Hypertension--World (1996 to 2006)Incidence of Stroke--World (1996 to 2006)Prevalence of Coronary Heart Disease--World (1996 to 2006)

Related Research

Release Date : 21-Nov-18

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.